- Home
- Publications
- Publication Search
- Publication Details
Title
NK cell-based therapeutics for lung cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 20, Issue 1, Pages 23-33
Publisher
Informa UK Limited
Online
2019-11-12
DOI
10.1080/14712598.2020.1688298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
- (2019) Jose M. Pacheco et al. Frontiers in Oncology
- Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
- (2019) Gaurav Nayyar et al. Frontiers in Oncology
- Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study
- (2019) Konrad Kokowski et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Neutrophil plasticity in the tumor microenvironment
- (2019) Morgan Giese et al. BLOOD
- Nivolumab plus ipilimumab in non-small-cell lung cancer
- (2019) Martin Reck et al. Future Oncology
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
- (2019) Alfredo Addeo et al. Frontiers in Oncology
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
- (2019) Silvia Pesce et al. Frontiers in Immunology
- Natural killer cell cytotoxicity and its regulation by inhibitory receptors
- (2018) Santosh Kumar IMMUNOLOGY
- Role of natural killer cells in lung cancer
- (2018) Ozge Nur Aktaş et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
- (2018) Yayi He et al. Drug Design Development and Therapy
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- Natural Killer Cells: Development, Maturation, and Clinical Utilization
- (2018) Alex M. Abel et al. Frontiers in Immunology
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
- (2018) Kathleen E. Fenerty et al. Journal for ImmunoTherapy of Cancer
- The Broad Spectrum of Human Natural Killer Cell Diversity
- (2017) Aharon G. Freud et al. IMMUNITY
- Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer
- (2017) Mao Lin et al. IMMUNOLOGY LETTERS
- Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Gro
- (2017) Stefan Stangl et al. INTERNATIONAL JOURNAL OF CANCER
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developmental and Functional Control of Natural Killer Cells by Cytokines
- (2017) Yang Wu et al. Frontiers in Immunology
- The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
- (2017) John P. Veluchamy et al. Frontiers in Immunology
- Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine
- (2017) Peter Vaupel et al. Frontiers in Immunology
- Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
- (2017) Jingyu Zhang et al. Science Advances
- CAR-T Cell Therapy for Lymphoma
- (2016) Carlos A. Ramos et al. Annual Review of Medicine
- Exploitation of natural killer cells for the treatment of acute leukemia
- (2016) Rupert Handgretinger et al. BLOOD
- Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
- (2016) Jesus I. Luna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging Immunotherapies in the Treatment of Non–small Cell Lung Cancer (NSCLC)
- (2015) Corey J. Langer AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The many interactions between the innate immune system and the response to radiation
- (2015) Serge M. Candéias et al. CANCER LETTERS
- DNAM-1 controls NK cell activation via an ITT-like motif
- (2015) Zhanguang Zhang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
- (2015) Daniel Morgensztern et al. Journal of Thoracic Oncology
- Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer
- (2015) Xiao Ding et al. Journal of Translational Medicine
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation
- (2015) Ludovic Martinet et al. Cell Reports
- Advantages and applications of CAR-expressing natural killer cells
- (2015) Wolfgang Glienke et al. Frontiers in Pharmacology
- NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
- (2015) Jinyu Zhang et al. Frontiers in Immunology
- Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial
- (2015) Hanno M. Specht et al. Frontiers in Immunology
- Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
- (2015) U. Koehl et al. OncoImmunology
- TGF-β1 Protein Expression in Non-Small Cell Lung Cancers is Correlated with Prognosis
- (2014) Ai-Li Huang et al. Asian Pacific Journal of Cancer Prevention
- Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells
- (2014) G. Hodge et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Effect of tumor cells and tumor microenvironment on NK-cell function
- (2014) Massimo Vitale et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: Retrospective clinical observation
- (2014) Guoqing Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Cutting Edge: The Metalloproteinase ADAM17/TNF- -Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
- (2014) P. Boutet et al. JOURNAL OF IMMUNOLOGY
- The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
- (2014) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins
- (2013) Lucas Ferrari de Andrade et al. IMMUNOLOGY AND CELL BIOLOGY
- Natural cytotoxicity receptors and their ligands
- (2013) Philip H Kruse et al. IMMUNOLOGY AND CELL BIOLOGY
- Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice
- (2013) Jeannette Cany et al. PLoS One
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect
- (2012) Nina Eissler et al. CANCER RESEARCH
- A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
- (2012) Noriko Shimasaki et al. CYTOTHERAPY
- Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity
- (2012) Jamie L Harden et al. IMMUNOLOGICAL INVESTIGATIONS
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
- (2012) Minu K. Srivastava et al. PLoS One
- Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes
- (2012) YOSHIKI SHIGEMATSU et al. Oncology Letters
- Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
- (2011) D V Tassev et al. CANCER GENE THERAPY
- Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer
- (2011) Sung Hoon Sim et al. CANCER SCIENCE
- Lung Cancer: Epidemiology, Etiology, and Prevention
- (2011) Charles S. Dela Cruz et al. CLINICS IN CHEST MEDICINE
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment
- (2011) Stefan Stangl et al. RADIOTHERAPY AND ONCOLOGY
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
- (2010) Eleni G. Iliopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NF- B Links CO2 Sensing to Innate Immunity and Inflammation in Mammalian Cells
- (2010) E. P. Cummins et al. JOURNAL OF IMMUNOLOGY
- Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody
- (2010) S. Stangl et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
- (2009) T. Baessler et al. BLOOD
- 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells
- (2009) B. Altvater et al. CLINICAL CANCER RESEARCH
- Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target
- (2009) Riad Abès et al. Expert Review of Clinical Immunology
- Molecular Basis for E-cadherin Recognition by Killer Cell Lectin-like Receptor G1 (KLRG1)
- (2009) Seiko Nakamura et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells
- (2009) Leslie Elsner et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future
- (2008) Marc Daëron et al. IMMUNOLOGICAL REVIEWS
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- (2008) A. Kruschinski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started